

LIST OF ABBREVIATIONS

| | |
|----------------------------|---|
| % | : Percentage |
| χ^2 | : Chi-square test. |
| ACD | : Anemia of chronic disease. |
| ACE | : Angiotensin-converting enzyme. |
| ACR | : American College of Rheumatology. |
| AER | : Albumin excretion rate. |
| ANA | : Antinuclear antibody. |
| ANOVA | : Analysis of variance. |
| Anti-ds DNA | : Anti-double stranded DNA. |
| anti-ENA | : Anti-extractable nuclear antigens, RNA-associated antigens. |
| Anti-RNP Ab | : Anti-ribonucleoprotein. antibody |
| anti-Smith antibody | : Anti-smith antibody. |
| APC | : Antigen presenting cell. |
| APS | : Anti-phospholipid syndrome. |
| ARBs | : Angiotensin receptor blockers. |
| ATP | : Adenosine tri-phosphate. |
| AZA | : Azathioprine. |
| BAFF | : B lymphocyte activating factor. |
| BCAP | : B-Cell adaptor for phosphoinositide 3-kinase. |
| BCR | : B cell antigen receptor. |
| BILAG | : British isles lupus assessment group scale. |
| Bld.Urea | : Blood urea. |
| BLyS | : B lymphocyte stimulating factor. |
| C | : Complement. |
| C₃ | : Complement 3. |
| C3bi receptor | : Inactivated complement component 3 receptor 3 subunit |
| C₄ | : Complement 4. |
| CD14 | : Cluster of differentiation 14. |
| CD44+pERM+ cells | : CD44+ T cells associated with pERM signalling partner. |
| CKD | : Chronic kidney disease. |
| CMV | : Cytomegalovirus |
| COPD | : Chronic obstructive pulmonary disease. |
| CpG | : Unmethylated cytidine-phosphate guanosine. |
| CRP | : C-reactive protein. |
| CVID | : Common variable immunodeficiency -like disease. |
| CYC | : Cyclophosphamide. |
| DAMPs | : Damage associated molecular patterns |
| DCs | : Dendritic cells. |
| DHEA | : Dehydroepiandrosterone. |
| DNA | : Deoxyribonucleic acid. |
| dsRNA | : Double-stranded ribonucleic acid. |
| EBV | : Epstein-barr virus. |
| ECAM | : Endothelial cell adhesion molecules. |
| ECG | : Electrocardiography. |
| ECLAM | : European consensus lupus activity measure. |

| | |
|--------------------------|---|
| ECM | : Extracellular matrix |
| EDTA | : Ethylene diamine tetra acetic acid. |
| eGFR | : Estimated glomerular filtration rate. |
| ELISA | : Enzyme-linked immunosorbent assay. |
| EM | : Electron microscopy. |
| EPO | : Erythropoietin. |
| ESR | : Erythrocyte sedimentation rate. |
| ESRD | : End stage renal disease. |
| FcγIIIB | : Fragment crystallizable gamma receptor type IIIB. |
| FDA | : Food and Drug Administration. |
| FITC | : Fluorescein isothiocyanate. |
| F-test | : One-way ANOVA test. |
| G | : Guanosine. |
| GAS | : Gamma-activated sequence. |
| GBM | : Glomerular basement membrane. |
| GN | : Glomerulonephritis. |
| Gp96 | : A heat shock protein 90 paralogue, |
| GTPases | : Guanosine triphosphatases. |
| GWAS | : Genome-wide association studies. |
| Hb | : Haemoglobin. |
| HBV | : Hepatitis B virus. |
| HCV | : Hepatitis C virus. |
| HDMEC | : Human dermal endothelial cells. |
| HIV-1 | : Human immunodeficiency virus type 1. |
| HLA | : Human leucocytic antigen. |
| HMEC-1 | : Immortalized skin-derived endothelial cells. |
| HMGB1 | : High mobility group proteins. |
| hpf | : High-power field. |
| HRP | : Streptavidin-horseradish peroxidase |
| hs-CRP | : High sensitive CRP. |
| HSP | : Heat shock proteins. |
| HUS | : Haemolytic-uraemic syndrome. |
| IC | : Immune complex. |
| IDA | : Iron deficiency anemia. |
| IF | : Immunofluorescence microscopy. |
| IFNAR | : Interferon alpha receptor. |
| IFNLR | : Interferon lambda receptor |
| IFN-α | : Interferon alpha |
| IL | : Interleukin. |
| IL-28Rα | : Interleukin28 receptor alpha |
| iNKT | : Invariant natural killer T cell. |
| IRF | : Interferon regulatory factor. |
| ISGF3 | : Interferon stimulated gene factor 3. |
| ISGs | : Interferon stimulated genes. |
| ISN/ RPS | : International Society of Nephrology /Renal Pathology Society. |
| ISRE | : Interferon stimulated response elements. |
| ITGAM | : Integrin, alpha M; C ₃ bi receptor. |
| Jak1 | : Janus kinase1. |
| K HCO₃ | : Potassium bicarbonate. |

| | |
|--|--|
| KH₂ PO₄ | : Potassium dihydrogen phosphate. |
| LAI | : Lupus activity index. |
| LFA-1 | : Lymphocyte function-associated antigen-1. |
| LM | : Light microscopy. |
| LN | : Lupus nephritis. |
| LPS | : Lipopolysaccharide. |
| LRR | : Leucin-rich repeat. |
| LSD | : Least significance difference (Post Hoc test). |
| Mal | : Myd88-adaptor-like. |
| mCRP | : Monomeric CRP. |
| MD-2 | : Myeloid differentiation protein-2 |
| mDCs | : Myeloid dendritic cells. |
| MDRD | : Modification of Diet in Renal Disease. |
| MHC | : Major histocompatibility complex. |
| MMF | : Mycophenolate mofetil. |
| MPA | : Mycophenolic acid. |
| mRNA | : Messenger RNA. |
| MyD88 | : Myeloid differentiation primary response 88. |
| n | : Number |
| n.d. | : Not determined |
| N.S. | : Not significant. |
| NA | : Nucleic acid. |
| Na EDTA | : Sodium ethylene diamine tetra acetic acid. |
| Na₂ H PO₄ | : Disodium monohydrogen phosphate. |
| NA-TLRs | : NA-sensing TLRs. |
| NF-κB | : Nuclear factor kappa B |
| NH₄ CL | : Ammonium chloride. |
| NK | : Natural killer cell. |
| ODN | : Oligodeoxynucleotides. |
| Ox-LDL | : Oxidized low density lipoprotein. |
| PAMPs | : Pathogen-associated molecular patterns. |
| PAS | : Periodic Acid Schiff. |
| PBMCs | : Peripheral blood mononuclear cells. |
| PBS | : Phosphate buffered saline. |
| pDC | : Plasmacytoid dendritic cells. |
| PE | : Phycoerythrin. |
| pERM | : Phosphorylated ezrin, radixin, and moesin. |
| PGA | : Physician global assessment. |
| PI3K | : Phosphoinositide 3-kinase. |
| PIP2 | : Phosphatidylinositol 4,5-bisphosphate. |
| PLKs | : Polo like kinases. |
| poly (I:C) | : Polyinosinic-polycytidylic acid. |
| PRAT4 | : Protein associated with toll-like receptor4 |
| PRRs | : Pattern recognition receptors. |
| PTECs | : Proximal tubular epithelial cells. |
| QoL | : Quality of life. |
| R | : Range. |
| RBCs | : Red blood cells. |
| RIG | : Retinoic acid inducible gene |
| RLRs | : Retinoic acid inducible gene I-like receptors. |

| | |
|--------------------------------|---|
| RNA | : Ribonucleic acid. |
| Ro/SS-A antigen | : Sjögren's syndrome-A antigen |
| ROC curve | : Receiver-operating characteristic curve. |
| ROS | : Reactive oxygen species. |
| S.Cr | : Serum creatinine. |
| SD | : Standard Deviation. |
| SELENA | : Safety of Estrogens in Lupus Erythematosus National Assessment trial. |
| SIGIRR | : Single immunoglobulin interleukin-1 receptor related molecule. |
| siRNA | : Small interfering RNA. |
| SIS | : National institutes of health SLE index score. |
| SLAM | : Systemic lupus activity measure. |
| SLE | : Systemic lupus erythematosus. |
| SLEDAI | : SLE disease activity index. |
| SLICC | : Systemic Lupus International Collaborating Clinics. |
| SNPs | : Single-nucleotide polymorphisms. |
| snRNA | : Small nuclear RNA. |
| snRNPs | : Small nuclear ribonucleoproteins. |
| SPSS | : Statistical Package for the Social Sciences. |
| ssRNA | : Single-stranded ribonucleic acid. |
| STAT | : Cytosolic signal transducers and activators of transcriptions. |
| t- | : Student t- Test. |
| T reg | : Regulatory T cell. |
| t test | : The student t-test. |
| T.WBC's | : Total white blood cell count. |
| TGF-β | : Tumour growth factor beta. |
| Th | : T helper cell. |
| TICAM-1 | : TIR-containing adaptor molecule-1. |
| TIR | : Toll/interleukin-1 receptor. |
| TIRAP | : TIR domain-containing adaptor protein. |
| TLR | : Toll-like receptor. |
| TMB | : Tetramethylbenzidine. |
| TNFAIP2 | : Tumor necrosis factor alpha-induced protein 2. |
| TNF-α | : Tumour necrosis factor alpha. |
| TREX1 | : Three prime repair exonuclease 1. |
| TRIF | : TIR domain-containing adaptor inducing interferon- β . |
| tRNA | : Transfer RNA. |
| TTP | : Thrombocytopenic purpura. |
| Tyk2 | : Tyrosine-protein kinase 2. |
| U | : Uridine. |
| U.Alb/U.Cr | : Urinary albumin/ creatinine ratio. |
| UNC93B1 | : Unc-93 homolog B1 |
| US | : United States. |
| UV | : Ultraviolet rays. |
| WBCs | : White blood cells. |
| α | : Alpha. |

| | | |
|-----------------|---|---------------|
| β | : | Beta. |
| γ | : | Gamma. |
| ϵ/τ | : | Epsilon/ Tau. |
| κ | : | Kappa. |
| λ | : | Lambda. |
| ω | : | Omega. |

LIST OF TABLES

| Table | | Page |
|-------|--|------|
| I. | The American College of Rheumatology (ACR) criteria for classification of systemic lupus erythematosus | 7 |
| II. | The Systemic Lupus International Collaborating Clinics (SLICC) classification criteria of systemic lupus erythematosus | 8 |
| III. | International Society of Nephrology /Renal Pathology Society Classification of Lupus Nephritis 2003 | 13 |
| IV. | Active and Chronic Lesions In Lupus Nephritis | 14 |
| V. | Types of toll like receptors (TLRs), their locations, damage-associated molecular pattern molecules (DAMPs), pathogen-associated molecular pattern molecules (PAMPs), adaptors, secretory products, and the diseases in which they have been implicated | 22 |
| VI. | SLEDAI 2000 (SLEDAI– 2K) data collection form | 31 |
| VII. | Clinical manifestations in patients with systemic lupus erythematosus with and without nephropathy | 42 |
| VIII. | Haemoglobin concentration, total white blood cell count, monocytes count and platelets count in patients with systemic lupus erythematosus without nephropathy | 43 |
| IX. | Haemoglobin concentration, total white blood cell count, monocytes count and platelets count in patients with systemic lupus erythematosus with nephropathy | 44 |
| X. | Haemoglobin concentration, total white blood cell count, monocytes count and platelets count in control subjects | 45 |
| XI. | Blood urea, serum creatinine, estimated glomerular filtration rate and urinary albumin/urinary creatinine ratio in patients with systemic lupus erythematosus without nephropathy | 46 |
| XII. | Blood urea, serum creatinine, estimated glomerular filtration rate and urinary albumin/urinary creatinine ratio in patients with systemic lupus erythematosus with nephropathy | 47 |
| XIII. | Blood urea, serum creatinine, estimated glomerular filtration rate and urinary albumin/urinary creatinine ratio in control subjects | 48 |
| XIV. | Mean \pm standard deviation and statistical analysis of haemoglobin concentration, total white blood cell count, monocytes count, platelets count, blood urea, serum creatinine, estimated glomerular filtration rate and urinary albumin/urinary creatinine ratio in patients with systemic lupus erythematosus with and without nephropathy and control subjects | 49 |
| XV. | Erythrocyte sedimentation rate, C-reactive protein, complement 3 and complement 4, in patients with systemic lupus erythematosus without nephropathy | 54 |
| XVI. | Erythrocyte sedimentation rate, C-reactive protein, complement 3 and | 55 |

| | | |
|----------------|--|----|
| | complement 4, in patients with systemic lupus erythematosus with nephropathy | |
| XVII. | Erythrocyte sedimentation rate, C-reactive protein, complement 3 and complement 4 in control subjects | 56 |
| XVIII. | Mean \pm standard deviation and statistical analysis of erythrocyte sedimentation rate, C-reactive protein, complement 3 and complement 4, in patients with systemic lupus erythematosus with and without nephropathy and control subjects | 57 |
| XIX. | Antinuclear antibody (ANA) titer in patients with systemic lupus erythematosus with and without nephropathy and control subjects | 60 |
| XX. | Anti-double stranded DNA (Anti-ds DNA IU/ml) in patients with systemic lupus erythematosus with and without nephropathy and control subjects | 61 |
| XXI. | The activity index in patients with systemic lupus erythematosus with and without nephropathy | 62 |
| XXII. | Toll like receptors 7 (TLR 7 cell/ μ l) in patients with systemic lupus erythematosus with and without nephropathy and control subjects | 63 |
| XXIII. | Serum interleukin 29 (IL-29 pg/ml) in patients with systemic lupus erythematosus with and without nephropathy and control subjects | 64 |
| XXIV. | Mean \pm standard deviation and statistical analysis of antinuclear antibody titer, anti-double stranded DNA, toll-like receptor 7 and serum interleukin-29, in patients with systemic lupus erythematosus with and without nephropathy and control subjects | 65 |
| XXV. | Renal biopsy of patients with systemic lupus erythematosus with nephropathy | 70 |
| XXVI. | Statistical correlation between TLR7, IL-29 and the different studied parameters in patients with systemic lupus erythematosus without nephropathy | 75 |
| XXVII. | Statistical correlation between the different studied parameters in patients with systemic lupus erythematosus without nephropathy | 76 |
| XXVIII. | Statistical correlation between TLR7, IL-29 and the different studied parameters in patients with systemic lupus erythematosus with nephropathy | 77 |
| XXIX. | Statistical correlation between the different studied parameters in patients with systemic lupus erythematosus with nephropathy | 78 |
| XXX. | Statistical correlations of the activity and chronicity indices in renal biopsy of patients with lupus nephritis | 79 |

LIST OF FIGURES

| Figure | | Page |
|--------|---|------|
| 1 | Mechanisms involved in the pathogenesis of systemic lupus erythematosus and lupus nephritis | 11 |
| 2 | Histopathological light micrograph of lupus nephritis (LN) | 15 |
| 3 | Differential use of adaptors by the different types of toll-like receptors (TLRs) and the transcription factors they activate | 21 |
| 4 | Roles of toll like receptors (TLRs) in inflammation and anti-inflammation | 24 |
| 5 | The signalling pathway of type III interferons (IFNs) compared with type II and type I IFNs | 26 |
| 6 | Haemoglobin concentration (g/dl) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 50 |
| 7 | Total white blood cell count and monocyte count ($\times 10^3/\text{mm}^3$) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 50 |
| 8 | Platelet count (cell $\times 10^3/\text{mm}^3$) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 51 |
| 9 | Blood urea (mg/dl) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 51 |
| 10 | Serum creatinine (mg/dl) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 52 |
| 11 | Estimated glomerular filtration rate ($\text{ml}/\text{min}/1.72\text{m}^2$) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 52 |
| 12 | Urinary albumin/urinary creatinine ratio (mg/g) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 53 |
| 13 | Erythrocyte sedimentation rate (ESR) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 58 |
| 14 | C-reactive protein (CRP) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 58 |
| 15 | Complement 3 and complement 4 (mg/ml) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 59 |

| | | |
|-----------|--|----|
| 16 | Antinuclear antibody (ANA) titer in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 66 |
| 17 | Anti double stranded DNA (IU/ml) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 66 |
| 18 | Systemic lupus erythematosus disease activity index (SLEDAI) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) | 67 |
| 19 | Toll-like receptor 7 (cell/ μ l) in patients with systemic lupus erythematosus without (Group I) and with nephropathy (Group II) and control subjects (Group III) | 67 |
| 20 | Receiver operating characteristic curve (ROC) for Toll-like receptor 7 for discrimination of patients with lupus nephritis from patients with systemic lupus erythematosus. | 68 |
| 21 | serum interleukin 29 (pg/ml) in patients with systemic lupus erythematosus without (Group I) and with (Group II) nephropathy and control subjects (Group III) | 68 |
| 22 | Receiver operating characteristic curve (ROC) for interleukin 29 for discrimination of patients with lupus nephritis from patients with systemic lupus erythematosus. | 69 |
| 23 | Correlation between toll like receptor 7 (TLR7) (cell/ μ l) and interleukin 29 (IL29) (pg/ml) in patients with systemic lupus erythematosus without nephropathy (Group I) and patients with lupus nephritis (Group II) | 80 |
| 24 | Correlation between toll like receptor 7 (TLR7) (cell/ μ l) and both antinuclear antibody (ANA) (titer) and anti-double stranded DNA (anti-ds DNA) (IU/ml) in patients with systemic lupus erythematosus without nephropathy (Group I) and patients with lupus nephritis (Group II) | 80 |
| 25 | Correlation between Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and both interleukin 29 (IL29) (pg/ml) and toll like receptor 7 (TLR7) (cell/ μ l) in patients with systemic lupus erythematosus without nephropathy (Group I) and patients with lupus nephritis (Group II) | 81 |
| 26 | Correlation between C reactive protein (CRP) (mg/l) and both toll like receptor 7 (TLR7) (cell/ μ l) and interleukin 29 (IL29) (pg/ml) in patients with systemic lupus erythematosus without nephropathy (Group I) and patients with lupus nephritis (Group II) | 81 |
| 27 | Correlation between interleukin 29 (IL29) (pg/ml) and both antinuclear antibody (ANA) (titer) and anti-double stranded DNA (anti-ds DNA) (IU/ml) in patients with systemic lupus erythematosus without nephropathy (Group I) and patients with lupus nephritis (Group II) | 82 |
| 28 | Correlation between estimated glomerular filtration rate (e-GFR) | 82 |

(ml/min/1.73m²) and both toll like receptor 7 (TLR7) (cell/μl) and interleukin 29 (IL29) (pg/ml) in patients with systemic lupus erythematosus without nephropathy (Group I) and patients with lupus nephritis (Group II)

- 29** Correlation between serum creatinine (mg/dl) with both C-reactive protein (CRP) (mg/l) and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in patients with systemic lupus erythematosus without nephropathy (Group I) 83
- 30** Correlation between serum creatinine (mg/dl) with both complement 3 (C3) (mg/ml) and complement 4 (C4) (mg/ml) in patients with systemic lupus erythematosus without nephropathy (Group I) 83
- 31** Correlation between urinary albumin/urinary creatinine ratio (mg/g) and both complement 3 (C3) (mg/ml) and complement 4 (C4) (mg/ml) in patients with systemic lupus erythematosus without nephropathy (Group I) 84
- 32** Correlation between serum creatinine (mg/dl) with both C-reactive protein (CRP) (mg/l) and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in patients with lupus nephritis (Group II) 84
- 33** Correlation between serum creatinine (mg/dl) with both complement 3 (C3) (mg/ml) and complement 4 (C4) (mg/ml) in patients with lupus nephritis (Group II) 85
- 34** Correlation between urinary albumin/urinary creatinine ratio (mg/g) and both complement 3 (C3) (mg/ml) and complement 4 (C4) (mg/ml) in patients with lupus nephritis (Group II) 85
- 35** Correlation between the activity index in renal biopsy and both toll like receptor 7 (TLR7) (cell/μl) and interleukin 29 (IL29) (pg/ml) in patients with lupus nephritis (Group II) 86
- 36** Correlation between the chronicity index in renal biopsy and interleukin 29 (IL29) (pg/ml) in patients with lupus nephritis (Group II) 86